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Abstract
Background: There is a vast and contradictory literature concerning the effect of the spleen and
particularly of splenectomy on tumor growth. Sometimes splenectomy seems to inhibit tumor
growth, but in other cases it seems, paradoxically, to facilitate both oncogenesis and the growth of
established tumors.
Approach:  In this essay I have selected from this large literature a few papers that seem
particularly instructive, in the hope of extracting some understanding of the rules governing this
paradoxical behavior.
Conclusion:  In general, whether splenectomy enhances or inhibits tumor growth seems to
depend primarily upon the ratio of spleen to tumor. Small proportions of spleen cells usually
stimulate tumor growth, in which case splenectomy is inhibitory. Larger proportions of the same
cells, especially if they are from immunized animals, usually inhibit tumor growth, in which case
splenectomy results in tumor stimulation.
Spleen cell/tumor cell mixtures
For a general but detailed description of the spleen and its
functions see [1].
In one of my own studies, I showed that when a relatively
small proportion of spleen cells from specifically immu-
nized donors was admixed with sarcoma cells prior to
implantation of the mixture into radiated and thymect-
omized syngeneic mice, growth of the resulting tumor was
relatively stimulated [2]. Larger proportions of the same
immune cell population inhibited growth when mixed
with the tumor. Non-immune spleen cells or cells that
were immune to a different tumor were also stimulatory,
but to a significantly much lesser degree. These observa-
tions support the conclusion that the immune response to
a tumor transplant is biphasic; a quantitatively small
spleen-cell response enhances tumor growth, but a larger
quantity of the same reactants, relative to the amount of
tumor, is inhibitory.
To reiterate, as illustrated in Figure 1 (which first appeared
in [3]), immune spleen cells, and seemingly the very same
spleen cells, can be either stimulatory or inhibitory to the
growth of an implanted tumor depending upon the quan-
titative proportions of tumor cells (antigen) to spleen
cells. A small ratio of immune spleen cells is stimulatory
to tumor growth while a sufficiently large ratio is inhibi-
tory. In this essay, I have defined immunogenicity as the
capacity of a prior implant of syngeneic tumor to alter the
growth of a subsequent challenge implant of that same
tumor.
It is beyond the scope of this essay to discuss in any detail
the possible molecular mechanisms by which spleen cells
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are able to facilitate or inhibit tumor growth, or which
among the many cellular species in the spleen may be
responsible for these contrasting abilities. However, it
may not be amiss to cite a wonderful essay by Harry
Rubin, which drew attention to numerous demonstra-
tions of the fact that the degree of cellular aggregation can
determine and control the growth and differentiation of
cells both in vitro and in vivo [4]. One may speculate that
the varied effects on tumor growth produced by varied
proportions of spleen cells might result from an altera-
tion, by splenic elements, of the adhesiveness of the
tumor cell membranes, thereby perhaps altering the effec-
tive density of a tumor cell population.
Transplanted tumors
Spleen cells need not be directly mixed with the tumor
cells for the spleen to exert a dosage-dependent effect.
Implanted tumors are also influenced by the remote
spleen as is shown by the effect of prior splenectomy. In
one study [5] in which a large dose, 1 × 107, of Meth 1
tumor cells was inoculated, splenectomy reduced tumor
growth. In relation to Figure 1, the system apparently fell
to the left of "c" on the curve with a larger dose of tumor
cells (a lower proportion of spleen cells) and was moved
in the direction of "a" by splenectomy. In contrast, when
only 5 × 105 tumor cells were inoculated, splenectomy
improved the tumor-takes; with this smaller dose of
tumor cells (a higher proportion of spleen cells) the sys-
tem apparently fell on a position well to the right of "c"
and was moved toward "c" by splenectomy. A similar
effect of dosage on the activity of the spleen visa-vis a
tumor implant was also clearly identified by Nordlund &
Gershon [6] and by Chang & Turk [7]. It is apparent that
whether splenectomy stimulates or inhibits tumor growth
depends upon which side of point "c", in Figure 1, the sys-
tem lies when the spleen is intact.
Splenic variation within a single inbred strain
Data suggest a marked variability in susceptibility to
chemical sarcogenesis among mice of a single highly
inbred strain. The earlier appearance of a methylcholan-
threne-induced sarcoma in one animal of a pair marked
that mouse as having about a 70% chance of developing
the next tumor before its paired mate did so [8]. It was
concluded that the increased susceptibility was not caused
by the earlier tumor, but that the earlier tumor merely
indicated a greater susceptibility to tumor formation that
had been present before the first tumor appeared. This
conclusion seems justified for five separate reasons. (1)
Control mice, which had been exposed to a syngeneic
tumor-implant rather than to tumor induction, were not
more susceptible to subsequent carcinogenesis [8]. (2) It
has been established that immunological cross-reactions
among independently induced sarcomas are exceedingly
rare [9], so the likelihood that an earlier tumor might
influence the appearance of a second independent tumor
by immunological means seems remote. (3) Putative
reduction of the immunogenicities of the tumors by
reducing the carcinogen concentration eliminated the sus-
ceptibility differences [10]. (4) Reduction of the immuno-
logical capacities of the animals by thymectomy and
radiation also eliminated the apparent differences in
tumor susceptibility among the mice [10]. (5) Most
importantly, as I will soon detail, the variability in suscep-
tibility was transferable from mouse to mouse via spleen
cells before any tumor had been induced and before the
carcinogen had been administered [11]. Thus, it seems
safe to conclude that animals of a single inbred strain do
vary markedly, presumably for epigenetic reasons, in their
immunological susceptibilities to the induction of immu-
nogenic tumors; a variability that must be attributable, at
least in part, to variations in their spleens that predate the
administration of carcinogen.
It is well understood that differences among many pheno-
typic characters depend upon epigenetically determined
differences in gene activity rather than actual differences
among the genes involved. Epigenetic influences deter-
mine whether the same genome will specify a liver as
opposed to a nerve cell or a patch of white skin on some
C57 Bl mice, but not on others. Thus, it is not surprising
to discover that splenic variations, even within an inbred
strain, may have a profound effect on chemical oncogen-
esis. Indeed, while there appear to be many mutations
within cancers, many tumors may probably have their
genesis in epigenetic aberrations rather than, or as well as,
in mutations [12]. The results make it clear that epigenetic
factors play a large part in determining the activity of the
spleen vis-a-vis chemically-induced cancers; it is epigenet-
ically-induced physiological variation, largely in the
spleen, not just chance timing of some transformational
Curve of tumor growth as influenced by proportions of  immune reactants Figure 1
Curve of tumor growth as influenced by proportions of 
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event, that determines which animals of an inbred strain
get tumors before others.
The experiments showing the transfer of variability from
one mouse to another prior to exposure to the carcinogen,
and thus prior to the inception of the first tumor, gave an
unexpected and seemingly paradoxical result [11]. The
experiment was designed for analysis by pairs. Both mice
in each initial pair, A and B, were splenectomized and
then given a standard subcutaneous dose of methylcho-
lanthrene. The spleen from mouse A was transferred to a
third animal, A+, and the spleen from B was transferred to
a fourth mouse, B+. A+ and B+ were then also given the
carcinogen. In nine out of nine trial pairs (p < 0.001), if a
tumor appeared in A before one appeared in B, then a
tumor appeared in B+ before one appeared in A+; con-
versely, if tumor appeared in B before A, the next tumor
appeared in A+ before B+. Thus, spleen cells taken from
the donor that subsequently (after splenectomy) proved
relatively susceptible to oncogenesis conferred a relative
resistance to oncogenesis on the recipient; while spleen
cells from the other donor, the more resistant of the pair,
imparted relative susceptibility on the recipient.
A logical explanation for this seemingly paradoxical result
may reside in the fact that in each transfer the whole
minced spleen of a single donor was transferred intraperi-
toneally to a single radiated, thymectomized recipient.
Thus, a very significant proportion of the animal's entire
lymphoid population was transplanted. If the donor
spleen was of a type to confer relatively high susceptibility
to oncogenesis on a secondary host, it seems reasonable
that the donor of that spleen might be left with a relative
paucity of tumor-facilitating capacity. Conversely, a donor
that had originally been relatively resistant to oncogenesis
probably became relatively susceptible by virtue of
splenectomy; but the spleen transferred the donor's origi-
nal relative resistance to the recipient.
Other effects on oncogenesis
A number of other studies also show that splenectomy
often has profound effects on carcinogenesis. Female rats
were splenectomized and then exposed to 9,10-dimethyl-
1,2-benzanthracene to induce mammary tumors.
Splenectomy decreased the rate of appearance of these
immunogenic tumors [13,14]. Other work suggests that
chemical oncogenesis produces specific tolerance to, or
relative stimulation of, the induced tumor and its antigens
[15,16]. Thus, it seems that oncogenesis, at least in sys-
tems in which immunogenic tumors are produced (most
chemical carcinogen systems), is often subject to inhibi-
tion by splenectomy. Prior to splenectomy, these systems
probably lie near "b" or "c" on the Figure 1 curve.
By analogy with the already-discussed experiment in
which spleen cells were mixed with tumor cells in varying
proportions, one might predict that, in systems in which
tumors of low immunogenicity are produced, oncogene-
sis might result in growth-inhibitory rather than stimula-
tory splenic activity, and that splenectomy would facilitate
rather than inhibit tumor growth in such cases. However,
it should be realized that there may be two types of non-
immunogenic tumors. Looking at Figure 1, it is apparent
that there are two places on the curve where a tumor elic-
iting that particular ratio of reaction would be considered
non-immunogenic: at "a" and at "e". If a tumor induces
an immune reaction that puts it near "e", any reduction in
the quantity of immune reactants, as by splenectomy,
would be expected to enhance tumor growth. However, if
the immune response places the tumor anywhere between
"a" and "c", any such reduction in the proportion of
immune reactants would be expected to inhibit tumor
growth and/or incidence. I have recently proposed that an
immune reaction may be necessary in vivo for oncogenesis
to occur [17]; if this were really so, it is possible that no
tumors could fall directly on point "a".
The preceding analysis appears to be largely consistent
with observation. Squartini [18] showed that when
tumors appear to be relatively non-immunogenic, as do
viral mammary tumors in the mouse, and the effective
ratio of immunogen to spleen cells is decreased by
splenectomy, tumorigenesis is facilitated. The facilitation
of tumor growth suggests that prior to splenectomy this
system fell near "e" on the Fig. 1 curve, and the apparent
lack of immunogenicity of the tumors was due to a bal-
ance between facilitating and inhibiting immune reac-
tions.
In the human, splenectomy for trauma has little if any
effect on the subsequent occurrence of cancers [19,20]. If
some human tumors are immunogenic while others are
much less so, splenectomy will sometimes cause facilita-
tion and sometimes inhibition of tumor development
and thus have little net effect. It is also possible that many
human tumors might actually fall at or near "a" on the
curve. Perhaps a more likely explanation for the absence
of any effect of splenectomy on the incidence of tumors in
humans is that if there were too long an interval between
splenectomy and tumor development, compensatory
mechanisms might negate much of the effect of the
splenectomy [21].
Alimentary tract
A paper by Hull et al. [22], which might seem inconsistent
with my thesis, examined the effect of splenectomy upon
the appearance of 1,2 dimethylhydrazine-induced intesti-
nal tumors in the mouse. Contrary to expectation,
splenectomy appeared to enhance the appearance of car-Theoretical Biology and Medical Modelling 2006, 3:23 http://www.tbiomed.com/content/3/1/23
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cinomas, although it did not increase the incidence of
benign lesions. No direct measure of the immunogenicity
of the tumors appears to be available, but one usually
expects chemically-induced tumors to be immunogenic
and to fall between "b" and "c" on the biphasic curve. Two
very different explanations seem possible: perhaps the
tumors were indeed so immunogenic that they fell to the
right of "c"; and/or the tumors were intrinsically immuno-
genic but the immunity was blocked.
The latter explanation could be considered because of the
possible induction of oral tolerance. Orally-fed cancer tis-
sue induces a non-cross-reactive attenuation of cellular
anti-tumor host responses [23]. Oral tolerance may be
prevented by prior splenectomy [24]. I suggest the follow-
ing speculative scenario: the intestinal tumors in the Hull
experiment [22], especially the more malignant, may have
induced oral tolerance. In the animal of origin, they might
thus have fallen near "e" on the biphasic curve and
appeared to be non-immunogenic; splenectomy would
have moved the system toward "c" and therefore resulted
in relative facilitation of the tumors.
A further possible problem is presented by a report that
implants of two different carcinogen-induced mouse
colon cancers were also enhanced rather than inhibited by
splenectomy [25]. Oral tolerance cannot be a factor in
tumor implants, as opposed to tumor induction.
Although the immunogenicities of the carcinomas are
again not known, they were probably highly immuno-
genic and one of them induced splenomegaly. Probably
they were so immunogenic that they fell far to the right of
"c", perhaps near "f" on the curve in Figure 1, and splenec-
tomy then moved them in the direction of "c".
Splenectomy as therapy
The possibility that splenectomy is an effective therapy for
established cancers has attracted much interest and intro-
duces yet another variable; the timing of splenectomy.
Favorable reports from Japan suggesting that splenectomy
is beneficial in the course of surgery for stomach cancer
may be marginally correct, but subsequent studies have
not been encouraging [26,27].
However, splenectomy markedly delayed the course of
B16 melanoma growth [28], and Stolfi et al. [29] reported
that, in a murine spontaneous mammary cancer system,
splenectomy combined with enucleative tumor surgery
reproducibly increased the cure rates in comparison to
enucleative surgery alone. This mammary tumor system
yields tumors with little or no detectable immunogenicity
by the classical test of transplantation into putatively
immunized mice [30]. In the tumor system employed by
Stolfi et al., allowing the tumor to grow large before enu-
cleation and splenectomy might have allowed the spleen
to be exposed to sufficient antigen to shift the system from
near "e" (non-immunogenic) to "c" or beyond. Splenec-
tomy under these circumstances might then be expected
to produce the relative inhibition of tumor growth that
was actually observed [29]. This very positive result in
what is essentially a non-immunogenic tumor system sug-
gests that therapeutic splenectomy may merit further
investigation.
Miscellaneous effects
Another variable that probably affects the action of the
spleen significantly is the age of the organ. The young
spleen seems more likely than the spleen from an older
animal to exert a facilitating effect upon tumor growth
[31]. The very fact that tumors in older animals tend to
grow more slowly may reflect the decline with age of the
tumor-stimulating capacity of the spleen [32,33].
A number of reports have suggested that perioperative all-
ogeneic transfusion may worsen the prognosis in gastric
cancer. Weitz et al. [34] reported that this worsening was
mediated by the spleen in a mouse model and was pre-
vented by splenectomy. Splenectomy had no harmful
effect in the absence of a blood transfusion. In a some-
what analogous mouse experiment, I found that a large
allogeneic blood transfusion profoundly stimulated the
growth of, in this case, a transplantable allogeneic tumor.
The stimulation was abolished by prior splenectomy [35].
It will be remembered that non-specifically immune or
even non-immune spleen cells facilitate tumor growth to
some extent when mixed in small proportions with
implanted tumor cells [2], so it is perhaps not surprising
that allogeneic transfusions might enhance the spleen's
facilitation of tumor growth. What role oral tolerance may
play in the gastric carcinoma system is uncertain [23].
It has been reported that splenectomy has a differential
effect on primary versus metastatic lesions [36] or upon
less malignant versus more highly malignant tumors [37].
In the course of liver carcinogenesis, it has been noted that
later, more mature hyperplastic nodules grow to form
metastasizing hepatocarcinomas if injected into the
spleen, but do not grow if injected into numerous other
sites such as under the kidney capsule [38]. It is interesting
in this connection that Hammond (see [17]) reported that
a higher immune capacity in the host promoted tumor
progression.
Conclusion
The effects of the spleen on tumor growth are exceedingly
complex. Nevertheless, allowing for a few possibly dis-
cordant notes, it appears that most effects can generally be
explained on the basis of the quantitative ratio of immune
system/antigen: a higher ratio (less tumor and/or antigen)
favors inhibition of growth, but a lower ratio (lessTheoretical Biology and Medical Modelling 2006, 3:23 http://www.tbiomed.com/content/3/1/23
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immune reactants) stimulates the tumor. The facilitating
effect of relatively small quantities of immune spleen cells
seems to be a positive stimulation of tumor growth and
not a mere blocking of tumor inhibition. It is possible that
many tumors, considered nonimmunogenic on the basis
of classical transplantation tests, may actually elicit an
immune response that is balanced between the inhibitory
and the tumor-stimulatory properties primarily by the
spleen, i.e. they may be at "e" on the biphasic curve.
Highly immunogenic tumors would lie at a distance from
"a" as well as from "e".
Probably any observation can be accommodated in terms
of the biphasic curve in Figure 1, but finding a place for an
observation on the curve does not necessarily mean that
the interpretation is correct. However, the curve does pro-
vide a rational way of thinking about some complex inter-
actions and suggests the need to titrate the immune
reaction against tumor size and antigenicity whenever
possible.
The promising results of therapeutic splenectomy in sev-
eral systems suggest that further studies of this phenome-
non are desirable, albeit perhaps not with tumors of the
alimentary tract.
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